This cell line is frequently employed to investigate the effects of chemotherapeutic agents or targeted therapies on osteosarcoma, focusing on pathways regulating apoptosis (e.g., BAX/BCL2) and angiogenesis (e.g., VEGF inhibition) [15,16]. Here, VEGFA is linked to osteosarcoma.